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Many  drugs  have  been  developed  that  are  able  to  modulate  the  GABAergic  system, 
which is involved in anxiety, depression, epilepsy, insomnia, and learning and memory. 
The  recent  observation  that  the  GABAA  receptor  is  underexpressed  in  the  fragile  X 
syndrome, an inherited mental retardation disorder, therefore raised hopes for targeted 
therapy of the disorder. This review summarizes the lines of evidence that demonstrate a 
malfunction of the GABAergic  system. The GABAergic  system  clearly emerges as an 
attractive target for therapy of the fragile X syndrome, and thus provides an excellent 
example of how genetic research can lead to unique opportunities for treatment. 
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INTRODUCTION 
Fragile X syndrome is the most frequent cause of inherited mental retardation affecting approximately 1 
in 5000 individuals[1]. The common genetic defect is an expanding CGG repeat (dynamic mutation) in 
the 5’ untranslated region of the fragile X mental retardation 1 (FMR1) gene. Elongation of this repeat 
above a threshold of 200 copies induces hypermethylation of the CpG island in the promoter region, 
leading to transcriptional silencing and, consequently, absence of the FMR1 protein product, FMRP[2,3]. 
The loss of FMRP is the basic defect underlying fragile X syndrome[4]. FMRP is a RNA-binding protein 
that interacts with various neuronal mRNAs, and is involved in the regulation of mRNA translation, 
transport,  and  stability.  At  the  synapses,  FMRP  plays  a  role  in  mRNA  transport  and  local  protein 
synthesis, and is therefore implicated in synaptic plasticity, a mechanism believed to underlie learning and 
memory[5,6].  Absence  of  FMRP  might  lead  to  deregulation  of  many  neuronal  mRNAs,  eventually 
cumulating in the fragile X phenotype[7]. 
Genetically modified animal models, including Fmr1 knockout mice and dFmr1-deficient fruit flies 
(Drosophila melanogaster), have contributed substantially to our understanding of the molecular deficits 
in  the  fragile  X  syndrome[8,9,10].  Fmr1  knockout  mice  exhibit  macro-orchidism,  mild  cognitive 
abnormalities, hyperactivity, and increased susceptibility to audiogenic seizures, features compatible with 
the  clinical  symptoms  observed  in  fragile  X  patients[11,12].  In  addition,  dendritic  spines  of  Fmr1 Heulens et al.: The GABAergic System in the Fragile X Syndrome  TheScientificWorldJOURNAL (2010) 10, 2198–2206 
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knockout mice are long and thin, and show an increased density, also similar to observations made in 
human  patients[13,14,15].  Moreover,  electrophysiological  measurements  showed  a  reduced long-term 
potentiation (LTP) in the cortex and an increased long-term depression (LTD) in the hippocampus of 
Fmr1 knockout mice[16,17,18]. The Drosophila model shows several behavioral abnormalities, such as 
abnormal  eclosion,  courtship  behavior,  and  circadian  rhythms,  and  displays  an  abnormal  neuronal 
morphology[19]. 
Despite  novel  insights  into  the  pathophysiology  of  the  disease,  a  specific  therapy  for  fragile  X 
patients is lacking. Current treatments are mostly symptom based, rather than specifically targeting the 
underlying  neuronal  defect  (reviewed  in  [20,21]).  Therefore,  it  is  of  utmost  importance  to  further 
elucidate the cellular and molecular consequences of the FMR1 mutation in order to identify new and 
specific targets potentially suitable for treatment of the disease. The two most prominent pathways with 
therapeutic potential involved in the fragile X pathogenesis involve the gamma aminobutyric acid type A 
(GABAA) receptor and the metabotropic glutamate receptor (mGluR)[7,22]. This review will focus on the 
involvement of the GABAergic pathway in fragile X syndrome, as the mGluR theory has been amply 
reviewed most recently[23,24]. 
THE GABAA RECEPTOR 
GABAA receptors are the main inhibitory receptors in the brain. GABAA receptors are assembled as 
pentamers  from  19  known  different  subunits  (ʱ1–6,  β1–3,  γ1–3,  δ,  ε,  θ,  π,  and  ρ1–3)  in  a  nonrandom 
fashion[25,26]. Different types of GABAA receptors have different physiological and pharmacological 
properties[27]. Most subtypes are expressed at the postsynaptic cleft, while the ʱ5- and δ-containing 
subtypes are located at extrasynaptic sites. The ρ subunits are expressed only in the retina, where they 
assemble in a specialized set of GABAA receptors, previously known as GABAC receptors[25]. GABAA 
receptors are ionotropic receptors. GABA-induced stimulation  occurs at the interface of the ʱ and β 
subunits, and results in the opening of the ion channel, resulting in an influx of Cl
– ions. Consequently, 
the  postsynaptic  membrane  hyperpolarizes,  causing  an  inhibitory  postsynaptic  potential  (IPSP)  that 
decreases the probability of firing. These ion channels are a target for a multitude of clinically relevant 
drugs, including diazepam, barbiturates, and neuroactive steroids[28]. 
In  inhibitory  neurons,  GABA  is  synthesized  from  glutamate  by  one  of  the  two  glutamic  acid 
decarboxylase enzymes present in vertebrates, GAD65 and GAD67. The neurotransmitter is transported 
to the synaptic cleft in vesicular inhibitory amino acid transporters (VIAAT) and released by an action 
potential. In the synaptic cleft, GABA binds its receptors at the postsynaptic density. Unbound GABA is 
either recycled to the presynaptic terminal by one of various GABA transporters or transported to the glial 
cells where it is metabolized to glutamate[7,29]. 
In  the  mammalian  central  nervous  system,  30–50%  of  all  neurons  are  GABAergic[30].  GABAA 
receptors are detected as early as embryonic day 13 (E13)[31]. Each GABAA receptor subunit exhibits a 
unique regional and temporal developmental expression pattern, e.g., ʱ5 and γ2 are present in most brain 
regions, whereas ʱ2 and ʱ3 show various expression profiles in different brain regions. In adult tissue, 
there  is  still  a  specific  regional  expression  pattern;  however,  it  differs  from  the  pattern  observed  in 
embryos, suggesting that the subunit composition and properties of the GABAA receptors are different in 
adult tissue compared to developing tissue.  
ALTERED EXPRESSION OF THE GABAergic SYSTEM IN FRAGILE X ANIMAL 
MODELS 
By performing expression profiling, our research group initially observed a reduced mRNA expression 
level of the ʴ subunit of the GABAA receptor in the hippocampus and neocortex of  Fmr1 knockout 
mice[32].  Using  real-time  PCR,  decreased  expression  of  seven  additional  subunits  of  the  GABA  A Heulens et al.: The GABAergic System in the Fragile X Syndrome  TheScientificWorldJOURNAL (2010) 10, 2198–2206 
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receptor was found in the cortex of Fmr1 knockout mice, including the ʱ1, ʱ3, and a4; β1 and β2; γ1 and γ2 
subunits[33]. Underexpression was also found for all three subunits (Grd, Rdl, and Lcch3) of the D. 
melanogaster  GABA  receptor,  suggesting  that  the  underexpression  is  evolutionarily  conserved.  The 
decreased expression of the GABA receptor is directly correlated with the absence of FMRP because the 
reduced mRNA levels can be restored to wild-type levels by introducing transgenic constructs expressing 
dFmr1 in the dFmr1
–/–fly. In addition, a down-regulation was also shown for several other components of 
the  GABAergic  system,  such  as  proteins  and  enzymes  involved  in  transport  (Gat1  and  Gat4)  and 
degradation  (Ssadh)  of  GABA,  and  in  the  clustering  and  targeting  of  the  GABAA  receptors  at  the 
postsynaptic membrane (Gephyrin) in the Fmr1 knockout mouse[34]. It is unclear whether the GABA-
synthesizing enzymes Gad1 and Gad2, encoding GAD67 and GAD65, respectively, are also present in 
reduced amounts. Our group reported decreased Gad1 mRNA levels in the cortex of a 10-week-old Fmr1 
knockout mouse and brain of the fragile X fly model[34]. In accordance with these data, Olmos-Serrano 
et  al.  described  reduced  GAD65/67  protein  levels  in  the  amygdala  of  3-week-old  Fmr1  knockout 
mice[35]. However, two other studies detected elevated GAD65/67 protein levels in the forebrain of adult 
Fmr1 knockout mice[36,37]. More data are needed to resolve this issue.  
In accordance with the underexpression at the mRNA level, decreased protein levels of the GABAA 
receptor  subunits  ʱ5,  βn,  and  δ  (the  only  subunits  analyzed)  were  demonstrated  in  the  hippocampus, 
cortex, diencephalons, and brain stem[36,38]. Most of these expression studies were performed in adult 
mice. Quantitative Western blotting of the forebrain of Fmr1 knockout X mice at postnatal day 5 and 12, 
in comparison with adult brain, showed that multiple components of the GABAergic system were found 
differentially expressed at one or two developmental stages, but not in all[37]. This selective down-
regulation  in  the  first  postnatal  weeks  may  have  severe  consequences  given  the  fact  that  there  is  a 
developmental switch from GABAergic excitation to inhibition early in the postnatal period. This brief 
time interval of excitatory GABAergic signaling plays a crucial role in neuronal development[39].  
FURTHER EVIDENCE FOR ABNORMALITIES OF THE GABAergic SYSTEM IN 
FRAGILE X SYNDROME 
A  dysfunction  of  the  GABAergic  system  in  fragile  X  syndrome  was  confirmed  by  many  other 
independent  groups  using  various  techniques.  Electrophysiological  recordings  suggested  a  decreased 
GABAergic  system  efficiency  in  Fmr1  knockout  mice  that  in  turn  may  interfere  with  cholinergic 
mechanisms[40]. Neurophysiological and immunofluorescence experiments also showed that absence of 
FMRP  is  associated  with  apparently  normal  striatal  glutamate  transmission,  but  abnormal  GABA 
transmission[41]. Recently, patch clamp recordings from subicular pyramidal cells showed that tonic 
GABA  currents  were  down-regulated  in  neurons  from  Fmr1  knockout  mice,  whereas  no  significant 
differences were observed in phasic currents[38]. Dictenberg et al.[42] demonstrated a reduced stimulus-
induced  localization  of  the  GABAA  receptor  δ  subunit  mRNA  in  cultured  hippocampal  dendrites  of 
neurons obtained from Fmr1 knockout mice. This might explain the reduced protein level of the δ subunit 
observed in the hippocampus of Fmr1 knockout mice[38]. Selby et al.[43] showed major defects in the 
neocortical and not in the hippocampal organization of GABAergic inhibitory circuits in Fmr1 knockout 
mice  that  could  be  linked  to  the  heightened  sensitivity  of  sensory-motor  gating  and  the  increased 
incidence of epilepsy seen in fragile X  syndrome. Reduction in the cell number and increase in the 
average soma area were only detected in a subpopulation of GABAergic interneurons, more specifically 
the parvalbumin-positive interneurons. Moreover, down-regulation of GABAergic neurons might partly 
explain the decrease in GABAA receptor subunits. Recently, study of the amygdala in Fmr1 knockout 
mice revealed major reductions in GABAA receptor–mediated synaptic and tonic inhibition[35]. This 
reduction could be ascribed to the decrease in the protein levels of GAD65/67, the reduced cellular and 
synaptic levels of GABA, and the reduction in inhibitory synapse number they found. Heulens et al.: The GABAergic System in the Fragile X Syndrome  TheScientificWorldJOURNAL (2010) 10, 2198–2206 
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THERAPEUTIC POTENTIAL OF THE GABAergic SYSTEM IN THE FRAGILE X 
SYNDROME 
As  GABAA  receptors  are  implicated  in  anxiety,  depression,  learning  and  memory,  epilepsy  and 
insomnia[44], processes also disturbed in the fragile X syndrome, we argued that the GABAA receptor 
might be a novel target for treatment of the fragile X syndrome[7]. 
The first pharmacological evidence that agonists of the GABAA receptor might be able to restore 
some of the deficits in the fragile X syndrome was reported recently in a fly model[45]. Fmr1-deficient 
animals die during development when raised on food containing increased levels of glutamate. Using this 
lethal phenotype, a chemical library of 2000 compounds was screened and nine molecules that rescued 
lethality  were  identified.  Interestingly,  three  of  them  were  implicated  in  the  GABAergic  pathway, 
including GABA itself, nipecotic acid, a GABA reuptake inhibitor, and creatinine, which is involved in a 
pathway that activates the GABAA receptor. Addition of each of these drugs to the food was able to 
restore known deficits of the fragile X flies, including Futsch overexpression and courtship behavior 
defects. Even the structural brain abnormalities in the form of morphological aberrations of the mushroom 
bodies, important for Drosophila learning and memory, could be largely rescued by addition of these 
drugs. 
Correcting fragile X syndrome by means of GABAergic drugs will be a major challenge for future 
translational research. Unlike in invertebrates, food administration of GABA is not feasible in patients, as 
the neurotransmitter hardly crosses the blood brain barrier. However, the pharmacology of the GABAA 
receptor is well documented and many GABAergic drugs that are able to modulate the activity of the 
receptor  are  readily  available[27].  Benzodiazepines,  such  as  diazepam,  are  the  best-known  proven 
anxiolytics, but these often exhibit unwanted side effects, including sedation and dependency. However, 
selective GABAA receptor agonists that target defined subtypes of the GABAA receptor are currently 
under investigation[46]. These drugs retain the anxiolytic activity, but are devoid of the sedation liability. 
In that way, they might be major candidates for challenging fragile X syndrome. An entirely different 
type of drugs are the neuroactive steroids, such as the endogenous allopregnanolone, that are potent 
modulators of the GABAA receptor. A promising example of a synthetic neurosteroid is ganaxolone, 
which has a favorable safety profile and is now in phase II clinical trials for treatment of catamenial 
epilepsy[47]. 
IS THE GABAB RECEPTOR ALSO INVOLVED IN THE FRAGILE X SYNDROME? 
GABAB  receptors  are  metabotropic  GABA  receptors.  These  members  of  the  G  protein-coupled 
superfamily are made up of a heterodimer of the membrane-spanning heptahelical proteins GABAB1 and 
GABAB2. The latter not only serves to escort GABAB1 to the cell surface, but also links the receptor to the 
G  protein,  whereas  GABAB1  is  necessary  for  agonist  activation.  GABAB  receptors  are  found  both 
presynaptically  and  postsynaptically.  Upon  activation,  presynaptic  GABAB  receptors  suppress 
neurotransmitter release through the inhibition of Ca
2+ channels or through second messenger–mediated 
effects[48]. Postsynaptic receptors induce a slow inhibitory postsynaptic potential by activation of G 
protein-coupled, inwardly rectifying, potassium channels[49]. Mice lacking functional GABAB receptors 
show  hyperactivity  and  epileptic  seizures,  indicating  that  GABAB  activity  is  crucial  for  normal 
physiological processes[50]. 
It has been suggested that GABAB receptors at glutamatergic terminals might serve as heteroreceptors 
regulating glutamate release[51]. Activation of GABAB receptors at glutamatergic spines is dependent on 
the spilled-over GABA from the inhibitory synapses.  There is no evidence for an altered amount of 
GABAB  receptors  in  fragile  X  syndrome[37].  However,  electrophysiological  experiments  indicated 
reduced GABA concentrations in the synaptic cleft of Fmr1 knockout mice[35]. Therefore, it is well 
possible that this reduced amount of GABA spill over from the inhibitory synapses results in a reduced 
inhibition  of  neurotransmitter  release  by  the  presynaptic  GABAB  receptors  located  on  glutamatergic Heulens et al.: The GABAergic System in the Fragile X Syndrome  TheScientificWorldJOURNAL (2010) 10, 2198–2206 
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synapses (Fig. 1). Reduced inhibition at excitatory synapses may at least in part explain the increased 
glutamatergic signaling observed in the absence of FMRP. Such elevated signaling is believed to underlie 
the increased LTD observed in Fmr1 knockout mice[17]. Thus, the GABAB receptor might provide a link 
with the so-called ―mGluR‖ theory, which postulates that increased signaling though group 1 mGluR 
receptors  is  responsible  for  the  symptoms  of  the  fragile  X  syndrome,  a  theory  that  has  been 
experimentally  validated[22,52].  This  link  predicts  that  stimulating  the  GABAB  receptor  is  able  to 
diminish the  excessive  metabotropic  glutamate  signaling  in  the fragile X  syndrome.  Indeed,  reduced 
seizures were observed in Fmr1 knockout mice after the administration of arbaclofen, a GABAB receptor 
agonist[35]. In fragile X children and adults, a phase II clinical trial with arbaclofen looks promising[53]; 
35%  of  the  patients  show  improvement,  whereby  mainly  the  higher  irritability/lower  sociability  and 
autism groups show benefit of the arbaclofen treatment.   
 
FIGURE 1. Hypothetical role of the GABAB receptor in fragile X syndrome. (1) GABA 
synthesis is reduced in the fragile X syndrome. (2) As a consequence, there might be a 
reduced amount of GABA spill over from the inhibitory synapses. (3) Reduced GABAB 
receptor stimulation results in a diminished neurotransmitter suppression by presynaptic 
GABAB  receptors  on  glutamatergic  neurons  and  may  explain  (part  of)  the  excessive 
glutamate signaling observed in the fragile X syndrome (4). Heulens et al.: The GABAergic System in the Fragile X Syndrome  TheScientificWorldJOURNAL (2010) 10, 2198–2206 
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CONCLUSION AND PERSPECTIVE 
Fragile X syndrome is an excellent example of how the identification of the causative gene in 1991[3] led 
to the characterization of the cellular and molecular pathways involved in the pathology of the disease, 
culminating in the discovery of molecular and biochemical pathways that may be targeted for rational 
therapy  of  the  disorder.  Several  trials  in  fragile  X  patients  have  been  initiated[20,54].  Mostly,  the 
glutamatergic system is targeted either directly or indirectly. A complete overview of the clinical trials 
ongoing and planned for the near future is presented elsewhere[21]. 
In addition to the excitatory mGluR pathway, abnormalities of the inhibitory GABAergic system in 
the fragile X syndrome have now been well established. GABA is the main inhibitory neurotransmitter in 
the  central  nervous  system.  Its  physiological  function  in  the  brain  is  mediated  predominantly  by 
interaction  with  ionotropic  GABAA  receptors,  but  also  by  metabotropic  GABAB  receptors[7].  Our 
research group has reported underexpression of several subunits of the GABAA receptor and of some 
molecules involved in GABA metabolism in the Fmr1 knockout mouse and Drosophila model[32,33,34]. 
This finding, together with other lines of evidence, has led to the hypothesis that deficiencies in the 
GABAergic system may significantly contribute to the clinical symptoms of fragile X syndrome[7]. As 
fragile X syndrome is also the leading cause of autism, it is interesting to note that a similar down-
regulation of the GABAA receptor was recently described in brains of subjects with autism[55]. The 
pharmacological properties of GABA receptors have been thoroughly studied, and several therapeutic 
agents acting on these receptors are either being evaluated in clinical trials or are already available for the 
treatment of neuropsychiatric disorders[7]. Promising studies in a mouse model for Down syndrome, 
which is shown to have an increased GABAA receptor–mediated inhibition, as opposed to the decreased 
GABAergic inhibition observed in Fmr1 knockout mice, demonstrated improvement of the cognitive 
deficits after administration of a GABAA receptor antagonist[56]. These results  suggest that GABAA 
receptor agonists, in addition to affecting behavior, might also be able to ameliorate cognitive functioning 
in fragile X patients. It is therefore encouraging to note that ganaxolone, a positive allosteric modulator of 
the GABAA receptor, is planned to be used for the first time in a pilot study with fragile X patients[57]. 
In conclusion, a dysfunction of the GABAergic system has been implicated in anxiety, depression, 
epilepsy,  insomnia,  and  learning  and  memory,  corresponding  to  the  clinical  symptoms  of  fragile  X 
patients[7,58].  Targeting  the  GABAergic  system  might  thus  be  a  promising  novel  strategy  for  the 
treatment of fragile X syndrome.  
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